Veru, Inc. (VERU) Reports Q3, Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. MU
6. USO
7. APGE
8. ABBV
9. DFTX
10. NAVN

Go back to Veru, Inc. (VERU) Reports Q3, Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories
(NASDAQ: VERU) Delayed: 2.96 --0 (-0%)
Previous Close $2.96    52 Week High $ 
Open $2.96    52 Week Low $ 
Day High $2.96    P/E N/A 
Day Low $2.96    EPS $ 
Volume 3,329